Mohamed Shafiu, MD
Nephrology · San Antonio, TXNPI 1174685648
Payments from drug & device makers
Across 404 payments — averaging $21.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- Fresenius USA Marketing, Inc.$976
- Amgen$861
- OPKO Pharmaceuticals, LLC$578
- Akebia Therapeutics Inc$494
- Novartis$455
- plus $3K from 24 others
What the payments were for
- Food & beverage$8,45699%
- Education$501%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 75 | $1,875 |
| Fresenius USA Marketing, Inc. | 55 | $976 |
| Amgen(2 entities) | 47 | $861 |
| OPKO Pharmaceuticals, LLC | 24 | $578 |
| Akebia Therapeutics Inc | 28 | $494 |
| Novartis | 17 | $455 |
| Daiichi Sankyo Inc. | 20 | $410 |
| Otsuka America Pharmaceutical, Inc. | 17 | $329 |
| Aurinia Pharma U.S., Inc. | 11 | $310 |
| Travere Therapeutics, Inc. | 17 | $309 |
| GSK | 18 | $301 |
| Merck | 15 | $283 |
| Boehringer Ingelheim | 6 | $240 |
| Vifor Pharma, Inc. | 11 | $196 |
| Bayer | 8 | $163 |
| Calliditas Therapeutics US Inc. | 6 | $133 |
| Novo Nordisk | 4 | $81 |
| ANI Pharmaceuticals, Inc. | 3 | $79 |
| Scpharmaceuticals Inc. | 3 | $74 |
| Shield Therapeutics Inc | 4 | $61 |
| Lilly USA, LLC | 2 | $51 |
| Outset Medical Inc | 1 | $43 |
| Arbor Pharmaceuticals, Inc. | 3 | $43 |
| Ardelyx, Inc. | 2 | $36 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $27 |
| Cormedix Inc. | 1 | $25 |
| Abbott | 1 | $20 |
| Ultragenyx Pharmaceutical Inc. | 1 | $19 |
| Mallinckrodt Hospital Products Inc. | 1 | $18 |
| Ironwood Pharmaceuticals, Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,506 in reported general payments places this provider in the 75th percentile of 1,070 nephrology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 388 | $386,813 |
| VelphoroSucroferric Oxyhydroxide | 51 | $170,175 |
| AuryxiaFerric Citrate | 51 | $138,135 |
| JardianceEmpagliflozin | 127 | $133,175 |
| MounjaroTirzepatide | 54 | $59,582 |
| OzempicSemaglutide | 48 | $53,466 |
| RayaldeeCalcifediol | 40 | $47,368 |
| VeltassaPatiromer Calcium Sorbitex | 24 | $17,139 |
| TarpeyoBudesonide | 12 | $13,448 |
| Sevelamer Carbonate | 60 | $13,205 |
| EntrestoSacubitril/Valsartan | 15 | $12,672 |
| DapagliflozinDapagliflozin Propanediol | 22 | $9,879 |
| Repatha SureclickEvolocumab | 13 | $6,919 |
| LinzessLinaclotide | 13 | $6,887 |
| LokelmaSodium Zirconium Cyclosilicate | 14 | $6,716 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Lokelma | $1,875 | $393,529402 claims |
| Fresenius USA Marketing, Inc.Velphoro | $976 | $170,17551 claims |
| Akebia Therapeutics IncAuryxia | $494 | $138,13551 claims |
| Boehringer IngelheimJardiance | $240 | $133,175127 claims |
| Lilly USA, LLCMounjaro | $51 | $59,58254 claims |
| Novo NordiskOzempic | $81 | $53,46648 claims |
| OPKO Pharmaceuticals, LLCRayaldee | $578 | $47,36840 claims |
| Calliditas Therapeutics US Inc.Tarpeyo | $133 | $13,44812 claims |
| NovartisEntresto | $455 | $12,67215 claims |
| ANI Pharmaceuticals, Inc.Valsartan | $79 | $2,19860 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,070 nephrology providers in Texas.
Other nephrology in San Antonio
- Pablo PergolaSan Antonio$14.2M
- Tahira AlvesSan Antonio$6.1M
- Carl DukesSan Antonio$5.9M
- Chinonye Ogbonnaya-OdorSan Antonio$4.6M
- Wesley CalhounSan Antonio$3.5M
- Shweta BansalSan Antonio$1.7M
- Robert SzewcSan Antonio$1.5M
- Rashid SharafSan Antonio$661K
- Varshasb BroumandSan Antonio$538K
- Luis VelezSan Antonio$505K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.